Exagen Q3 2023 Gaap EPS $(0.31) Beats $(0.46) Estimate, Sales $13.42M Beat $10.33M Estimate
Portfolio Pulse from saritha@benzinga.com
Exagen Inc. (NASDAQ:XGN) reported Q3 2023 earnings with a GAAP EPS of $(0.31), surpassing the $(0.46) estimate by 32.61%. Year-over-year, this represents a 34.04% improvement in EPS. Quarterly sales reached $13.42M, exceeding estimates by 29.87% but reflecting an 8.90% decrease from the previous year's same quarter.
November 13, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exagen Inc. reported better-than-expected Q3 earnings and revenue, with EPS beating estimates by 32.61% and sales surpassing expectations by 29.87%, despite a Y/Y decrease.
Exagen's stock is likely to experience a positive short-term impact due to the significant beat on both earnings and revenue estimates, which typically instills investor confidence and can lead to a rise in stock price. However, the year-over-year decrease in sales might temper some of the positive sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100